These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 19890336

  • 1. Therapy for metastatic RCC--questions remain.
    Breau RH, Leibovich BC.
    Nat Rev Urol; 2009 Nov; 6(11):580-1. PubMed ID: 19890336
    [No Abstract] [Full Text] [Related]

  • 2. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
    Stein MN, Flaherty KT.
    Clin Cancer Res; 2007 Jul 01; 13(13):3765-70. PubMed ID: 17606705
    [No Abstract] [Full Text] [Related]

  • 3. [New therapeutic regimes in metastasic renal-cell carcinoma].
    Bierer S, Hertle L, Nitschmann S.
    Internist (Berl); 2008 Jan 01; 49(1):114-7. PubMed ID: 18704353
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Zimmermann K, Schmittel A, Steiner U, Asemissen AM, Knoedler M, Thiel E, Miller K, Keilholz U.
    Oncology; 2009 Jan 01; 76(5):350-4. PubMed ID: 19321976
    [Abstract] [Full Text] [Related]

  • 13. Trials probe new agents for kidney cancer.
    Hampton T.
    JAMA; 2006 Jul 12; 296(2):155-7. PubMed ID: 16835411
    [No Abstract] [Full Text] [Related]

  • 14. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM.
    J Urol; 2008 Jan 12; 179(1):81-6; discussion 86. PubMed ID: 17997441
    [Abstract] [Full Text] [Related]

  • 15. Targeted therapy for metastatic renal cell carcinoma.
    Patel PH, Chaganti RS, Motzer RJ.
    Br J Cancer; 2006 Mar 13; 94(5):614-9. PubMed ID: 16465192
    [Abstract] [Full Text] [Related]

  • 16. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
    Desar IM, Mulder SF, Stillebroer AB, van Spronsen DJ, van der Graaf WT, Mulders PF, van Herpen CM.
    Acta Oncol; 2009 Mar 13; 48(6):927-31. PubMed ID: 19452305
    [No Abstract] [Full Text] [Related]

  • 17. [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
    Miller K, Bergmann L, Albers P, Jäger E, Jakse G, Geschwend JE, Marschner N.
    Aktuelle Urol; 2007 Jul 13; 38(4):328-30. PubMed ID: 17647172
    [Abstract] [Full Text] [Related]

  • 18. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.
    Herrmann E, Marschner N, Grimm MO, Ohlmann CH, Hutzschenreuter U, Overkamp F, Groschek M, Blumenstengel K, Pühse G, Steiner T.
    World J Urol; 2011 Jun 13; 29(3):361-6. PubMed ID: 21461939
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.